in assisted reproductive technologies, announced today that it has signed heads of terms with Novocellus to acquire the latter’s patented, non-invasive embryo selection technology, Embryosure.
UK company focused on the development and commercialization of the patented amino acid profiling, AAP, technology. AAP technology is a quantitative, non-invasive method for selecting those embryos that are most likely to lead to a successful pregnancy and live birth.
based on amino acid profiling, a technology discovered by professor Henry Leese at the University of York, UK. It involves measuring the turnover of natural amino acids by the embryo, achieved by analysing changes in the amino acid content of the embryo culture medium.
trials completed to date, amino acid profiling appears valuable in identifying those embryos most likely to lead to a successful pregnancy suggesting it could lead to a 25 per cent increase in the clinical pregnancy rate.
terms, Medicult has agreed to fund and manage a 400 patient retrospective trial in two to three UK clinics to statistically validate the extent to which the use of Embryosure will increase the chances of successful pregnancy compared to current visual techniques used to select the most viable embryo.
of this trial, Medicult will make milestone payments, in cash, shares or combinations thereof, to Novocellus as well as pay royalties on sales. Medicult would commercialise Embryosure itself and through its partner distribution companies worldwide.
BREAKING